Phenylbutazone + Bromhexine HCl

Applications: Pneumonia, Rhinitis, Respiratory tract infection, bronchitis, Respiratory Diseases, Bronchopneumonia

Phenylbutazone has analgesic, antiinflammatory, antipyretic, and mild uricosuric properties. The proposed mechanism of action is by the inhibition of cyclooxygenase, thereby reducing prostaglandin synthesis. Other pharmacologic actions phenylbutazone may induce include reduced renal blood flow and decreased glomerular filtration rate, decreased platelet aggregation, and gastric mucosal damage.

It enhances the transport of mucus by reducing its viscosity and increases cilia activity resulting in enhanced mucociliary clearance. This secretolytic and secretomotor effect in the bronchial tract facilitates expectoration and relieves cough

The following drug interactions have either been reported or are theoretical in humans or animals receiving phenylbutazone and may be of significance in veterinary patients:
FUROSEMIDE: Phenylbutazone may antagonize the increased renal blood flow effects caused by furosemide
HEPATOTOXIC DRUGS: Phenylbutazone administered concurrently with hepatotoxic drugs may increase the chances of hepatotoxicity developing
NSAIDS: Concurrent use with other NSAIDs may increase the potential for adverse reactions, however, some clinicians routinely use phenylbutazone concomitantly with flunixin in horses. One study did not show synergistic actions with flunixin, but did however, when phenylbutazone and ketoprofen were “stacked”.
PENICILLAMINE: May increase the risk of hematologic and/or renal adverse reactions
PENICILLIN G: Phenylbutazone may increase plasma half-life of penicillin
SULFONAMIDES: Phenylbutazone could potentially displace sulfonamides from plasma proteins; increasing the risk for adverse effects
WARFARIN: Phenylbutazone could potentially displace warfarin from plasma proteins; increasing the risk for bleeding